Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - glyceryl trinitrate, quantity: 54 mg - drug delivery system, transdermal - excipient ingredients: ethyl oleate; glyceryl laurate; acrylates/acrylamide copolymer - prevention of chronic stable angina pectoris due to coronary artery disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - glyceryl trinitrate, quantity: 36 mg - drug delivery system, transdermal - excipient ingredients: ethyl oleate; glyceryl laurate; acrylates/acrylamide copolymer - prevention of chronic stable angina pectoris due to coronary artery disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - glyceryl trinitrate, quantity: 18 mg - drug delivery system, transdermal - excipient ingredients: ethyl oleate; glyceryl laurate; acrylates/acrylamide copolymer - prevention of chronic stable angina pectoris due to coronary artery disease.

United States - English - NLM (National Library of Medicine)

bausch health us, llc - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 9 mg - transdermal nitroglycerin is indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of transdermal nitroglycerin is not sufficiently rapid for this product to be useful in aborting an acute attack. nitroglycerin is contraindicated in patients who are allergic to it. allergy to the adhesives used in nitroglycerin patches has also been reported, and it similarly constitutes a contraindication to the use of this product. do not use minitran in patients who are taking phosphodiesterase inhibitors (such as sildenafil, tadalafil, or vardenafil) for erectile dysfunction or pulmonary arterial hypertension. concomitant use can cause severe drops in blood pressure. do not use minitran in patients who are taking the soluble guanylate cyclase stimulator riociguat. concomitant use can cause hypotension.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals australia pty ltd - glyceryl trinitrate -

United States - English - NLM (National Library of Medicine)

graceway pharmaceuticals, llc - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 2.5 mg in 1 d - transdermal nitroglycerin is indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of transdermal nitroglycerin is not sufficiently rapid for this product to be useful in aborting an acute attack. allergic reactions to organic nitrates are extremely rare, but they do occur. nitroglycerin is contraindicated in patients who are allergic to it. allergy to the adhesives used in nitroglycerin patches has also been reported, and it similarly constitutes a contraindication to the use of this product.

New Zealand - English - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - glyceryl trinitrate 36mg (as 10mg/24h) - transdermal patch - 10 mg/24h - active: glyceryl trinitrate 36mg (as 10mg/24h) excipient: ethyl oleate glyceryl monolaurate ioa/acm copolymer

New Zealand - English - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - glyceryl trinitrate 18mg (as 5mg /24h) - transdermal patch - 5 mg/24h - active: glyceryl trinitrate 18mg (as 5mg /24h) excipient: ethyl oleate glyceryl monolaurate ioa/acm copolymer

Malta - English - Medicines Authority

meda pharmaceuticals limited skyway house, parsonage road, takeley, bishop''s stortford, cm22 6pu, united kingdom - glyceryl trinitrate - transdermal patch - glyceryl trinitrate milligram(s) - cardiac therapy

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - glyceryl trinitrate - transdermal patch - 5mg/24hour